annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM
Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets
Location: S406 (Vista Room)
CME credit: 1.5
Track(s): Melanoma/Skin Cancers
Kevin B. Kim, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
David B. Solit, MD—Co-Chair
Memorial Sloan-Kettering Cancer Center
4:30 PM Clinical outcome and pathologic features associated with NRAS mutation in
cutaneous melanoma. (Abstract #8500)
B. A. Devitt, W. Liu, R. Salemi, R. Wolfe, J. Kelly, A. Dobrovic, G. A. McArthur
4:45 PM Clinical responses to AZD6244 (ARRY-142886)-based combination therapy
stratified by gene mutations in patients with metastatic melanoma. (Abstract
#8501)
S. P. Patel, A. J. Lazar, S. Mahoney, C. Vaughn, N. Gonzalez,
N. E. Papadopoulos, P. Liu, J. R. Infante, P. LoRusso, K. B. Kim
Discussion
5:00 PM Neal Rosen, MD, PhD (Abstracts #8500–8501)
Memorial Sloan-Kettering Cancer Center
5:15 PM Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or
tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial
S0438. (Abstract #8502)
K. A. Margolin, J. Moon, L. E. Flaherty, C. D. Lao, W. L. Akerley, J. A. Sosman,
J. M. Kirkwood, V. K. Sondak, Southwest Oncology Group
5:30 PM Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant
BRAF kinase, in patients with metastatic melanoma and other solid tumors.
(Abstract #8503)
R. Kefford, H. Arkenau, M. P. Brown, M. Millward, J. R. Infante, G. V. Long,
D. Ouellet, M. Curtis, P. F. Lebowitz, G. S. Falchook
Discussion
5:45 PM Grant A. McArthur, PhD (Abstracts #8502–8503)
Peter MacCallum Cancer Centre
186